Australia's ReNerve rises on product market approval in Bahrain
28/05/2025 02:06
** Shares of ReNerve RNV.AX rise 9.5% to A$0.115, their highest levels since May 19 ** Stock on track for its strongest trading session since May 6, if gains sustain ** The biotech firm successfully gains marketing approval in Bahrain for its NervAlign nerve cuff product, which offers nerve repair solutions ** Stock down 34.3% YTD, including current session's moves (Reporting by Nikita Maria Jino in Bengaluru) ((Nikita.Jino@thomsonreuters.com;))
Recent news on Renerve
See all newsBrief: Renerve Says Positive FDA Feedback On Nervalign Nerve Guide Matrix
Brief: Renerve And Rmit Awarded A$499K Grant
Brief: ReNerve Posts Full-Year Loss Attributable Of A$5.6 Million
Brief: ReNerve Says Nervalign Nerve Cuff Receives CDSCO Marketing Approval In India
Australia's ReNerve rises on securing up to A$5 million funding facility